Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Health services and systems news

Show

From To
Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.

Published
26 January 2015
From
Street Insider
German insurers win discounts on Gilead's Sovaldi

The head of Gilead's German operations told the magazine that discounts from the list price of 60,000 euros (44,867 pounds) per treatment had been negotiated with four of Germany's statutory health insurers but declined to give the size of the discounts.

Published
26 January 2015
From
Yahoo News
HIV sweeps across eastern Europe amid economic crisis

HIV is spreading at a dangerous rate in nations around the Black Sea, passing a record 100,000 new cases yearly. Hotspots for the HIV rise are Ukraine and Russia - two countries facing economic crisis and armed conflict, factors which could provoke a further surge in the virus.

Published
26 January 2015
From
EUobserver
Ahead of Obama visit, MSF warns US pressure on India could impact access to medicines for millions

New intellectual property ‘think tank’ draft policy already showing alarming trend.

Published
23 January 2015
From
Medecins Sans Frontieres press release
London HIV Prevention Programme media contracts announced

Contracts have been awarded to a group of specialist media agencies (Team Enter, Manning Gottlieb, Carat) as part of the new London HIV Prevention Programme (LHPP) funded by London boroughs.

Published
21 January 2015
From
London Councils
Many HIV-positive people’s understanding of the law on HIV transmission is “weak and patchy”

Many people living with HIV in England have a limited understanding of the law which leaves them either at risk of prosecution for HIV transmission or with

Published
21 January 2015
By
Roger Pebody
New anti HIV drug dolutegravir is effective at low doses

The new anti-HIV integrase inhibitor dolutegravir is a highly potent drug. Alain Lafeuillade, a clinical researcher for 20 years in HIV disease, observed that Dolutegravir is highly effective alone in patients without integrase resistance. "Plasma viral load remained undetectable in my patients, and proviral HIV DNA in cells remained stable with only 50 mg 2 to 3 times a week," he said. He is proposing a low-dose dolutegravir monotherapy trial.

Published
21 January 2015
From
MMD Newswire
Peru: Patients Demand End to Monopoly on HIV Medication

Julio Cesar Cruz is an HIV patient and organizer with the Peruvian Network of Patients and Consumers . He participated in the demonstration and explained that, “The people who live with HIV in the country, are complaining that the Peruvian state is ...

Published
21 January 2015
From
TeleSUR
Ugandan gays go Bombastic

The front cover of Uganda's first ever gay magazine shows a man donning purple feathers and a glittering mask above a rainbow and the words: "Our Voices, Our Stories, Our Lives." Bombastic is distributed for free by Uganda's gay community, which has also launched an online radio station, Kuchu Radio, in a bid to fight prejudice.

Published
21 January 2015
From
DPA International
Gilead and AbbVie take hepatitis C battle to Europe

Europe is to become the next battleground between Gilead Sciences and AbbVie in their scramble to win share of the fast-growing market for hepatitis C drugs. The companies have been fighting a high-profile price war in the US over a new generation of blockbuster medicines that can cure most people with the virus within weeks. The pair are preparing to open a new front across the Atlantic after European regulators gave AbbVie’s hepatitis C treatment the green light on Friday.

Published
20 January 2015
From
Financial Times (free registration required)

Filter by country